Wroclaw

• A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended
  2024-514372-40-00 5 2022-04-12 Anterior ST-Elevation Myocardial Infarction
• A Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Radiological and Clinical Effects of Subcutaneous (SC) Ocrelizumab … Ended
  2023-505975-54-00 5 2022-03-28 Multiple Sclerosis (MS)
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia. Ended
  2024-510696-38-00 5 2022-03-08 Severe Hypertriglyceridemia.
• Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis Ended
  2023-506004-93-00 4 2022-03-01 Ulcerative Colitis (UC)
• Evaluation of safety i efficacy de-escalation antiplatelet strategies in acute coronary syndrome. Ended
  2024-518090-34-00 5 2022-02-07 Acute Coronary Syndrom (ACS)
• A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectivenes … Ended
  2022-501243-33-00 4 2022-02-03 Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s lymphoma, in pa
• VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Ended
  2023-509233-39-00 4 2022-01-20 Moderately to Severely Active Ulcerative Colitis
• A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer’s Disease Ended
  2024-512295-36-00 4 2021-12-06 Alzheimer Disease
• MENACWY=MEN7B-003 Ended
  2023-506449-40-00 9 2021-11-29 Infections, Meningococcal
• A Multicenter trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects with Moderate-to-Severe Atopic … Ended
  2024-514405-65-00 4 2021-11-22 Atopic Dermatitis
• A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain Ended
  2024-514934-19-00 5 2021-11-08 Post-surgical neuropathic pain
• A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended
  2022-500881-80-00 5 2021-10-29 Chronic Heart Failure With Reduced Ejection Fraction
• A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended
  2023-506170-12-00 4 2021-10-18 Alzheimer’s Disease
• A study to evaluate the efficacy and safety of repeating dose of benralizumab administered SC versus placebo in patients with Eosinophilic C … Ended
  2023-507987-38-00 5 2021-10-14 Severe CRSwNP patients with asthma.
• Efficacy and safety of obinutuzumab versus rituximab in combination with chemotherapy for adult patients with newly diagnosed CD20-positive … Ended
  2024-517389-40-00 4 2021-10-06 acute lymphoblastic leukemia
• A clinical study of tulisokibart for the treatment of ulcerative colitis (MK-7240-005) Ended
  2023-509741-12-00 4 2021-09-23 Ulcerative Colitis
• A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended
  2024-512879-13-00 5 2021-09-23 Neovascular age-related macular degeneration (wet AMD)
• Preoperative intraperitoneal chemotherapy in adjuvant hyperthermia adjunctive therapy in advanced gastric cancer with high-risk of peritonea … Ended
  2024-516042-18-00 10 2021-09-08 Gastric Carcinoma
• Research study on whether a combination of 2 medicines (NNC0194-0499 and Semaglutide) works in people with non-alcoholic steatohepatitis (NA … Ended
  2023-506961-74-00 4 2021-08-31 Non-alcoholic steatohepatitis (NASH)
• A study to learn how safe bimekizumab, how well it works and how it moves through the bloodstream in adolescents with moderate to severe pla … Ended
  2023-509832-24-00 4 2021-08-30 Moderate to Severe Plaque Psoriasis
• Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Ended
  2024-511925-71-00 5 2021-08-05 Acromegaly
• A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended
  2023-505203-23-01 5 2021-07-26 Severe asthma with an eosinophilic phenotype
• An extension study to learn if Bimekizumab is safe and works as a long-term therapy in adults with moderate to severe hidradenitis suppurati … Ended
  2024-511035-10-00 5 2021-06-23 Hidradenitis Suppurativa
• The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended
  2023-510174-13-00 5 2021-06-17 Chronic Obstructive Pulmonary Disease (COPD)

Showing 769–792 of 838 trials